Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 13/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | TTR | P02766 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | PTGES | O14684 | 1/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10467072 | 1.00 | ALOX5 (1.00) | ALOX5PTGS1PKMPTGS2APP | |
| SCHEMBL10468741 | 0.92 | ALOX5 (0.84) | ALOX5PTGS1PKMPTGS2APP | |
| SCHEMBL10468742 | 0.92 | ALOX5 (0.84) | ALOX5PTGS1PKMPTGS2APP | |
| SCHEMBL8392953 | 0.91 | ALOX5 (0.84) | ALOX5PTGS1PKMPTGS2APP | |
| SCHEMBL8392948 | 0.91 | ALOX5 (0.84) | ALOX5PTGS1PKMPTGS2APP | |
| SCHEMBL18509085 | 0.88 | ALOX5 (0.84) | ALOX5PTGS1PKMPTGS2APP | |
| SCHEMBL9695487 | 0.88 | ALOX5 (0.84) | ALOX5PTGS1PKMPTGS2APP | |
| SCHEMBL9579815 | 0.87 | ALOX5 (0.77) | ALOX5APPMAPTAKR1C3TTR | |
| SCHEMBL17833497 | 0.85 | ALOX5 (0.74) | ALOX5PTGS1APPMAPTAKR1C3 | |
| SCHEMBL10467077 | 0.82 | ALOX5 (0.70) | ALOX5PTGS1PTGS2AKR1C3TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4959503-A | Diarylalkanoids having activity as lipoxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 1990-09-25 | — | — | US | claimed |
| EP-4276089-A2 | MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY | Universite De Moncton (CA) | 2023-11-15 | — | — | EP | disclosed |
| US-11760715-B2 | Modulators of lipoxygenase and cyclooxygenase enzyme activity | UNIVERSITÉ DE MONCTON (CA) | 2023-09-19 | — | — | US | disclosed |
| US-11760715-B2 | Modulators of lipoxygenase and cyclooxygenase enzyme activity | UNIVERSITÉ DE MONCTON (CA) | 2023-09-19 | — | — | US | disclosed |
| EP-3423429-B1 | MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY | UNIV DE MONCTON (CA) | 2023-07-12 | — | — | EP | disclosed |
| US-20190119194-A1 | MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY | UNIVERSITE DE MONCTON (CA) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760715-B2 | Modulators of lipoxygenase and cyclooxygenase enzyme activity | ALOX12, ALOX15B, ALOX5 | ALOX5 3/4885PTGS1 13/4885PKM 2014/4885 |
| US-20190119194-A1 | MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY | ALOX12, ALOX15B, ALOX5 | ALOX5 3/4885PTGS1 13/4885PKM 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.